A Study to see how Phalatrikadi Yoga and Virechana karma help in managing abnormal blood lipid level.

An Open-Label Randomized Controlled Clinical Study to Evaluate the Efficacy of Phalatrikadi Yoga and Virechana Karma in the Management of Medoroga w.s.r. to Dyslipidemia - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/100834

Enrollment

Registered

2026-01-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E789- Disorder of lipoprotein metabolism, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who present with sign and symptoms of Medoroga w.s.r to Dyslipidemia as described in classical text. 2. Patients between the age group of 25-70 year of either gender will be selected for the study. 3. Serum lipid profile : Serum Cholesterol - 200 to 300 mg/dl Serum Triglycerides - 150 to 350 mg/dl Serum LDL - 100 to 200 mg/dl Serum VLDL - 30 to 100 mg/dl Serum HDL - 20 to 40 mg/dl 4. Volunteers fit for Virechana Karma. 5. Patients willing to participate in the trial.

Exclusion criteria

Exclusion criteria: 1. Patient not willing for the trial. 2. Patients who have completed participation in any other clinical trial during the last three months. 3. Patient having illness like Thyroid Dysfunction, Type II Diabetes Mellitus, Carcinoma, Renal and Hepatic disorders. 4. Patient having past history of Myocardial infarction, Unstable Angina and Congestive Cardiac Failure and Cerebrovascular Accident. 5. Patients Below the age of 30 yrs and above the age of 70 yrs. 6. Pregnant females and lactating mother. 7. Any other condition which the principal investigator thinks may jeopardize the study.

Design outcomes

Primary

Measure	Time frame
To evaluate the effect of Phalatrikadi Yoga and Virechana Karma in the management of Medoroga w.s.r. to Dyslipidemia.Timepoint: 3 and half months	—

Secondary

Measure	Time frame
To compare the efficacy of Pahalatrikadi Yoga and Virechana Karma with Rosuvastatin in the management of Medoroga w.s.r. to Dyslipidemia. To assess the clinical safety of Pahalatrikadi Yoga and Virechana Karma in patients of Medoroga w.s.r. to Dyslipidemia. Timepoint: 3 and half months	—

Countries

India

Contacts

Public ContactDr Anjali Verma

Rajiv Gandhi Govt Post Graduate Ayurvedic College and Hospital Paprola HP

drvijaychaudhary@gmail.com09418130228

Outcome results